Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 7.05
PACB's Cash to Debt is ranked higher than
68% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. PACB: 7.05 )
PACB' s 10-Year Cash to Debt Range
Min: 7.05   Max: No Debt
Current: 7.05

Equity to Asset 0.51
PACB's Equity to Asset is ranked higher than
61% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. PACB: 0.51 )
PACB' s 10-Year Equity to Asset Range
Min: -1.75   Max: 0.92
Current: 0.51

-1.75
0.92
F-Score: 3
Z-Score: -4.33
M-Score: -4.86
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -275.16
PACB's Operating margin (%) is ranked higher than
60% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. PACB: -275.16 )
PACB' s 10-Year Operating margin (%) Range
Min: -65237.04   Max: -275.16
Current: -275.16

-65237.04
-275.16
Net-margin (%) -281.37
PACB's Net-margin (%) is ranked higher than
60% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. PACB: -281.37 )
PACB' s 10-Year Net-margin (%) Range
Min: -64965.19   Max: -281.37
Current: -281.37

-64965.19
-281.37
ROE (%) -114.62
PACB's ROE (%) is ranked higher than
54% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. PACB: -114.62 )
PACB' s 10-Year ROE (%) Range
Min: -114.62   Max: -50.08
Current: -114.62

-114.62
-50.08
ROA (%) -58.22
PACB's ROA (%) is ranked higher than
58% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. PACB: -58.22 )
PACB' s 10-Year ROA (%) Range
Min: -86.75   Max: -38.68
Current: -58.22

-86.75
-38.68
ROC (Joel Greenblatt) (%) -839.57
PACB's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. PACB: -839.57 )
PACB' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1233.13   Max: -514.59
Current: -839.57

-1233.13
-514.59
Revenue Growth (%) 38.30
PACB's Revenue Growth (%) is ranked higher than
94% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. PACB: 38.30 )
PACB' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 38.3
Current: 38.3

0
38.3
EBITDA Growth (%) -56.40
PACB's EBITDA Growth (%) is ranked higher than
52% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. PACB: -56.40 )
PACB' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -56.4
Current: -56.4

EPS Growth (%) -55.30
PACB's EPS Growth (%) is ranked higher than
53% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. PACB: -55.30 )
PACB' s 10-Year EPS Growth (%) Range
Min: 0   Max: -55.3
Current: -55.3

» PACB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

PACB Guru Trades in Q1 2013

Jim Simons 318,416 sh (+30.59%)
Murray Stahl 12,000 sh (unchged)
Lee Ainslie 3,531,953 sh (unchged)
» More
Q2 2013

PACB Guru Trades in Q2 2013

Murray Stahl 12,000 sh (unchged)
Lee Ainslie 3,531,953 sh (unchged)
Jim Simons 276,000 sh (-13.32%)
» More
Q3 2013

PACB Guru Trades in Q3 2013

Lee Ainslie 5,814,719 sh (+64.63%)
Jim Simons 280,100 sh (+1.49%)
Murray Stahl 12,000 sh (unchged)
» More
Q4 2013

PACB Guru Trades in Q4 2013

Lee Ainslie 6,459,784 sh (+11.09%)
Murray Stahl 12,000 sh (unchged)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with PACB

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Lee Ainslie 2013-09-30 Add 64.63%0.17%$2.5 - $5.98 $ 4.3927%5814719
Jean-Marie Eveillard 2012-09-30 Sold Out 0.0013%$1.7 - $2.32 $ 4.39123%0
John Griffin 2012-06-30 Sold Out 0.05%$1.83 - $3.7 $ 4.3977%0
Jean-Marie Eveillard 2012-03-31 New Buy$2.94 - $5.04 $ 4.3918%150000
George Soros 2011-09-30 Sold Out 0.0018%$3.55 - $12.24 $ 4.39-44%0
George Soros 2011-06-30 New Buy$10.44 - $13.53 $ 4.39-63%10700
John Griffin 2011-03-31 New Buy0.21%$12.94 - $16.3 $ 4.39-71%870000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Pacific Biosciences of California, Inc.

Weekly CEO Buys Highlight: OPK, PACB, CUBI, ARCP, RLYP
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...

Ratios

vs
industry
vs
history
P/B 4.30
PACB's P/B is ranked higher than
65% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. PACB: 4.30 )
PACB' s 10-Year P/B Range
Min: 0.52   Max: 6.86
Current: 4.3

0.52
6.86
P/S 9.80
PACB's P/S is ranked higher than
54% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. PACB: 9.80 )
PACB' s 10-Year P/S Range
Min: 2   Max: 28.19
Current: 9.8

2
28.19
EV-to-EBIT 19.20
PACB's EV-to-EBIT is ranked higher than
57% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. PACB: 19.20 )
PACB' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 19.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.40
PACB's Price/Net Cash is ranked higher than
71% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. PACB: 6.40 )
PACB' s 10-Year Price/Net Cash Range
Min: 1.02   Max: 7.58
Current: 6.4

1.02
7.58
Price/Net Current Asset Value 5.50
PACB's Price/Net Current Asset Value is ranked higher than
76% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. PACB: 5.50 )
PACB' s 10-Year Price/Net Current Asset Value Range
Min: 0.95   Max: 6.54
Current: 5.5

0.95
6.54
Price/Tangible Book 4.20
PACB's Price/Tangible Book is ranked higher than
69% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. PACB: 4.20 )
PACB' s 10-Year Price/Tangible Book Range
Min: 0.8   Max: 4.98
Current: 4.2

0.8
4.98
Price/Median PS Value 1.30
PACB's Price/Median PS Value is ranked higher than
53% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. PACB: 1.30 )
PACB' s 10-Year Price/Median PS Value Range
Min: 0.51   Max: 1.59
Current: 1.3

0.51
1.59

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:P09.Germany
Pacific Biosciences of California, Inc., was incorporated in the State of Delaware in 2000. The Company's aim is to transform the way humankind acquires, processes and interprets data from living systems through the design, development and commercialization of innovative tools for biological research. To achieve this it has created a powerful platform called SMRT technology. Its initial focus is to use its SMRT technology in the DNA sequencing market where it has developed and are preparing to commercialize its first product, the PacBio RS, a novel third generation sequencing platform. The PacBio RS consists of an instrument platform that uses its proprietary consumables, including its SMRT Cells and reagent kits, providing a complete solution to the customer. The Company's strategy includes defining the future of biological analysis based on SMRT technology, focus initially on the DNA sequencing market, continually enhance product performance to increase market share, leverage platform to develop and launch additional applications, create a global community of users to enhance informatics capabilities and drive adoption of its products. The Company's competitors include Illumina Inc., Life Technologies Corporation and Roche Applied Science. The Company markets its products through a direct sales force in North America and the United Kingdom. The Company has received orders for its limited production release instrument from Baylor College of Medicine, the Broad Institute of MIT and Harvard, Cold Spring Harbor Laboratory, the U.S. Department of Energy Joint Genome Institute, The Genome Center at Washington University, Monsanto Company, the National Cancer Institute/SAIC-Frederick, the National Center for Genome Resources, the Ontario Institute for Cancer Research, Stanford University and Wellcome Trust Sanger Institute.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide